title: [Primary chronic glomerulonephritis with nephrotic syndrome. Treatment with prednisone and cyclophosphamide].
abstract: The authors present their long standing experience with immunosuppressive treatment of patients with nephrotic syndrome associated with primary chronic membranous, mesangioproliferative and mesangiocapillary glomerulonephritis. Of a total of 127 patients 99 were treated with prednisone and cyclophosphamide and 28 with cyclophosphamide only. Clinical remission developed in 89 patients (70%). Remissions developed independently on morphological findings and initial proteinuria, but more frequently in patients with a still normal glomerular filtration. In combined immunosuppression 77% of the treated patients developed remission, while only 48% treated with cyclophosphamide alone. 88% of the patients survive an average period of 10 years. From the investigation it is apparent that long-term and early combined immunosuppression has a favourable impact on the course of primary chronic glomerulonephritis with nephrotic syndrome.
authors.affiliation: II. interní klinika 1. LF UK, Praha.
authors.forename: V
authors.initials: V
authors.lastname: Knotková
authors.forename: K
authors.initials: K
authors.lastname: Nĕmecek
authors.forename: I E
authors.initials: IE
authors.lastname: Tarayeva
authors.forename: T N
authors.initials: TN
authors.lastname: Krasnova
mesh_terms: D000328:Adult; D002908:Chronic Disease; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D015432:Glomerulonephritis, Membranoproliferative / Q000150:complications / Q000188:drug therapy*; D015433:Glomerulonephritis, Membranous / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000150:complications / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage*
chemical_list: D003520:Cyclophosphamide; D011241:Prednisone
vernacular_title: Primární chronické glomerulonefritidy s nefrotickým syndromem. Lécba prednisonem a cyklofosfamidem.